|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BSG |
Gene summary for BSG |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BSG | Gene ID | 682 |
| Gene name | basigin (Ok blood group) | |
| Gene Alias | 5F7 | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P35613 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 682 | BSG | P126T-E | Human | Esophagus | ESCC | 1.89e-24 | 2.73e+00 | 0.1125 |
| 682 | BSG | P127T-E | Human | Esophagus | ESCC | 5.06e-45 | 1.04e+00 | 0.0826 |
| 682 | BSG | P128T-E | Human | Esophagus | ESCC | 1.61e-70 | 3.46e+00 | 0.1241 |
| 682 | BSG | P130T-E | Human | Esophagus | ESCC | 1.23e-98 | 2.92e+00 | 0.1676 |
| 682 | BSG | S43 | Human | Liver | Cirrhotic | 8.83e-06 | -2.35e-01 | -0.0187 |
| 682 | BSG | HCC1_Meng | Human | Liver | HCC | 5.26e-90 | 7.77e-02 | 0.0246 |
| 682 | BSG | HCC2_Meng | Human | Liver | HCC | 4.76e-50 | 2.05e-01 | 0.0107 |
| 682 | BSG | cirrhotic1 | Human | Liver | Cirrhotic | 1.21e-22 | 3.12e-01 | 0.0202 |
| 682 | BSG | cirrhotic2 | Human | Liver | Cirrhotic | 2.72e-29 | 3.54e-01 | 0.0201 |
| 682 | BSG | cirrhotic3 | Human | Liver | Cirrhotic | 2.02e-29 | 5.07e-01 | 0.0215 |
| 682 | BSG | HCC5 | Human | Liver | HCC | 4.36e-02 | 1.05e-01 | 0.4932 |
| 682 | BSG | Pt13.b | Human | Liver | HCC | 4.68e-37 | 3.66e-01 | 0.0251 |
| 682 | BSG | Pt14.a | Human | Liver | HCC | 1.21e-08 | 3.57e-01 | 0.0169 |
| 682 | BSG | Pt14.b | Human | Liver | HCC | 6.11e-04 | 1.63e-01 | 0.018 |
| 682 | BSG | S014 | Human | Liver | HCC | 1.43e-48 | 3.11e+00 | 0.2254 |
| 682 | BSG | S015 | Human | Liver | HCC | 6.04e-49 | 4.12e+00 | 0.2375 |
| 682 | BSG | S016 | Human | Liver | HCC | 2.00e-56 | 3.32e+00 | 0.2243 |
| 682 | BSG | S027 | Human | Liver | HCC | 4.32e-26 | 2.88e+00 | 0.2446 |
| 682 | BSG | S028 | Human | Liver | HCC | 2.94e-49 | 2.86e+00 | 0.2503 |
| 682 | BSG | S029 | Human | Liver | HCC | 9.26e-52 | 3.00e+00 | 0.2581 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
| GO:0072659 | Colorectum | AD | protein localization to plasma membrane | 122/3918 | 284/18723 | 2.86e-17 | 1.49e-14 | 122 |
| GO:1990778 | Colorectum | AD | protein localization to cell periphery | 129/3918 | 333/18723 | 5.51e-14 | 1.15e-11 | 129 |
| GO:0019058 | Colorectum | AD | viral life cycle | 119/3918 | 317/18723 | 6.18e-12 | 8.23e-10 | 119 |
| GO:0044403 | Colorectum | AD | biological process involved in symbiotic interaction | 99/3918 | 290/18723 | 1.02e-07 | 4.93e-06 | 99 |
| GO:0051701 | Colorectum | AD | biological process involved in interaction with host | 73/3918 | 203/18723 | 5.08e-07 | 1.88e-05 | 73 |
| GO:0043434 | Colorectum | AD | response to peptide hormone | 126/3918 | 414/18723 | 2.70e-06 | 7.86e-05 | 126 |
| GO:0052126 | Colorectum | AD | movement in host environment | 63/3918 | 175/18723 | 2.85e-06 | 8.11e-05 | 63 |
| GO:0007409 | Colorectum | AD | axonogenesis | 122/3918 | 418/18723 | 3.36e-05 | 6.15e-04 | 122 |
| GO:0001890 | Colorectum | AD | placenta development | 51/3918 | 144/18723 | 3.99e-05 | 7.16e-04 | 51 |
| GO:0046718 | Colorectum | AD | viral entry into host cell | 51/3918 | 144/18723 | 3.99e-05 | 7.16e-04 | 51 |
| GO:0061564 | Colorectum | AD | axon development | 132/3918 | 467/18723 | 8.40e-05 | 1.31e-03 | 132 |
| GO:0044409 | Colorectum | AD | entry into host | 51/3918 | 151/18723 | 1.60e-04 | 2.21e-03 | 51 |
| GO:0010038 | Colorectum | AD | response to metal ion | 106/3918 | 373/18723 | 3.22e-04 | 3.83e-03 | 106 |
| GO:0061458 | Colorectum | AD | reproductive system development | 116/3918 | 427/18723 | 1.11e-03 | 1.01e-02 | 116 |
| GO:0048608 | Colorectum | AD | reproductive structure development | 114/3918 | 424/18723 | 1.78e-03 | 1.47e-02 | 114 |
| GO:0051591 | Colorectum | AD | response to cAMP | 31/3918 | 93/18723 | 3.59e-03 | 2.58e-02 | 31 |
| GO:0007411 | Colorectum | AD | axon guidance | 64/3918 | 227/18723 | 5.41e-03 | 3.55e-02 | 64 |
| GO:0097485 | Colorectum | AD | neuron projection guidance | 64/3918 | 228/18723 | 6.02e-03 | 3.78e-02 | 64 |
| GO:00726591 | Colorectum | SER | protein localization to plasma membrane | 92/2897 | 284/18723 | 6.36e-13 | 1.86e-10 | 92 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BSG | SNV | Missense_Mutation | c.620C>T | p.Pro207Leu | p.P207L | P35613 | protein_coding | tolerated(0.47) | probably_damaging(0.915) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | ||
| BSG | SNV | Missense_Mutation | novel | c.121G>C | p.Glu41Gln | p.E41Q | P35613 | protein_coding | deleterious(0.04) | benign(0.282) | TCGA-OL-A5DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| BSG | SNV | Missense_Mutation | c.688G>C | p.Glu230Gln | p.E230Q | P35613 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| BSG | SNV | Missense_Mutation | novel | c.1000G>A | p.Glu334Lys | p.E334K | P35613 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| BSG | SNV | Missense_Mutation | novel | c.862G>C | p.Glu288Gln | p.E288Q | P35613 | protein_coding | tolerated(0.58) | benign(0.003) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| BSG | SNV | Missense_Mutation | novel | c.8C>T | p.Ala3Val | p.A3V | P35613 | protein_coding | tolerated(0.34) | benign(0.02) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| BSG | SNV | Missense_Mutation | c.238N>T | p.His80Tyr | p.H80Y | P35613 | protein_coding | tolerated(0.06) | possibly_damaging(0.686) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| BSG | SNV | Missense_Mutation | rs780701101 | c.386N>A | p.Arg129His | p.R129H | P35613 | protein_coding | tolerated(0.05) | benign(0.074) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BSG | SNV | Missense_Mutation | c.968N>T | p.Ala323Val | p.A323V | P35613 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BSG | deletion | Frame_Shift_Del | c.519delN | p.Gly175AlafsTer4 | p.G175Afs*4 | P35613 | protein_coding | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 682 | BSG | DRUGGABLE GENOME, TRANSPORTER | [131I]-Metuximab injection | |||
| 682 | BSG | DRUGGABLE GENOME, TRANSPORTER | Gavilimomab | GAVILIMOMAB | ||
| 682 | BSG | DRUGGABLE GENOME, TRANSPORTER | CHEMBL2109193 | GAVILIMOMAB | ||
| 682 | BSG | DRUGGABLE GENOME, TRANSPORTER | antibody | 405560467 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |